The GPAA1 Knockout SK-HEP-1 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human liver adenocarcinoma epithelial cell line. This polyclonal population carries a targeted disruption of the GPAA1 gene, achieved through CRISPR/Cas9-mediated gene editing, resulting in a heterogeneous pool of cells with loss-of-function mutations. The polyclonal format provides a genetically varied knockout model that is well-suited for pooled functional studies and high-throughput screening applications. As a mixed population, it recapitulates the diversity of gene-editing outcomes, enabling researchers to assess bulk phenotypic consequences of GPAA1 loss without the constraints of single-cell clonal selection.
The host cell line, SK-HEP-1, was originally isolated from the ascites of a patient with liver adenocarcinoma and serves as a well-characterized model for hepatic adenocarcinoma research. These epithelial cells exhibit properties relevant to hepatocellular carcinoma, including typical growth characteristics and metastatic potential. SK-HEP-1 cells are widely employed in cancer biology to investigate tumor cell adhesion, invasion, and signaling pathways. The integration of a GPAA1 knockout in this background creates a powerful tool for dissecting the role of glycosylphosphatidylinositol (GPI) anchor biosynthesis in liver cancer progression.
GPAA1 encodes the GPAA1 subunit of the GPI transamidase complex, a multi-protein enzyme essential for the post-translational attachment of GPI anchors to nascent proteins in the endoplasmic reticulum. GPAA1 functions within a complex that includes PIGK, PIGS, PIGT, and PIGU, mediating the cleavage of C-terminal signal peptides and covalent linkage of the preassembled GPI anchor. The gene is transcriptionally regulated by SP1 and NF-Y, and its activity directly controls the membrane presentation of GPI-anchored proteins such as alkaline phosphatase, CD55 (decay accelerating factor), and CD59 (protectin). Knockout of GPAA1 disrupts this process, trapping GPI-anchored proteins intracellularly and depleting them from the cell surface. This abolition of GPI anchor synthesis impinges on multiple downstream pathways, including protein trafficking, signal transduction, and cell-cell interactions.
Within the context of SK-HEP-1 liver adenocarcinoma cells, GPAA1 knockout provides a specific platform to investigate how loss of GPI anchor biosynthesis influences hepatic tumor cell behavior. Since GPI-anchored proteins are involved in cell adhesion, immune evasion, and receptor-mediated signaling, their absence from the plasma membrane can alter migratory properties, susceptibility to complement-mediated lysis, and responses to extracellular cues. This model may reveal dependencies of liver cancer cells on GPI-anchored factors, potentially linking GPI biosynthesis deficiencies to aspects of tumor biology such as metastasis or drug resistance. It also serves as a cellular system for studying developmental disorders like GPI biosynthesis deficiencies, epilepsy, and developmental delay that are associated with GPAA1 mutations.
Researchers can leverage this knockout model in a variety of experimental assays. Flow cytometry for CD55 and CD59 surface expression provides a robust readout of GPI anchor dysfunction, while western blotting of GPI-anchored proteins and alkaline phosphatase activity assays confirm intracellular accumulation and loss of enzymatic function, respectively. Immunofluorescence microscopy enables visualization of mislocalized GPI-anchored proteins, and cell viability assays can assess the functional impact of GPAA1 disruption. Typical research applications include dissecting GPI anchor biology, elucidating protein trafficking mechanisms, modeling hepatocellular carcinoma, and exploring membrane protein localization. For further information or to discuss custom applications, please contact Ascent Research.
